{"pmid":32420691,"title":"Active Therapy with Passive Immunotherapy May Be Effective in the Fight against Covid-19.","text":["Active Therapy with Passive Immunotherapy May Be Effective in the Fight against Covid-19.","Passive immunity against pathogens in epidemics has historical roots. Convalescent plasma (CP), plasma collected from individuals who have recovered from an infectious disease, has been used to confer therapeutic benefits in previous epidemics, including measles, mumps, and influenza, and remains the first line passive immunotherapy in emerging diseases, including the H1N1 influenza pandemic (2009) and now Covid-19 (1). Over the last several decades, as technology has developed to purify and manufacture plasma-derived immunoglobulin (IG) as a drug therapy, hyperimmune globulin (H-IG) formulations have been used as the second line of passive immunotherapies against these diseases.","Clin Transl Sci","Morabito, Christopher J","Gangadharan, Bagirath","32420691"],"abstract":["Passive immunity against pathogens in epidemics has historical roots. Convalescent plasma (CP), plasma collected from individuals who have recovered from an infectious disease, has been used to confer therapeutic benefits in previous epidemics, including measles, mumps, and influenza, and remains the first line passive immunotherapy in emerging diseases, including the H1N1 influenza pandemic (2009) and now Covid-19 (1). Over the last several decades, as technology has developed to purify and manufacture plasma-derived immunoglobulin (IG) as a drug therapy, hyperimmune globulin (H-IG) formulations have been used as the second line of passive immunotherapies against these diseases."],"journal":"Clin Transl Sci","authors":["Morabito, Christopher J","Gangadharan, Bagirath"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32420691","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1111/cts.12816","topics":["Treatment"],"weight":1,"_version_":1667159284535787520,"score":9.490897,"similar":[{"pmid":32453687,"title":"Position paper on the preparation of immune plasma to be used in the treatment of patients with COVID-19.","text":["Position paper on the preparation of immune plasma to be used in the treatment of patients with COVID-19.","Passive immunotherapy with plasma derived from convalescent patients recovering from SARS-CoV-2 infection can be a promising approach in the treatment of COVID-19 patients. It is important that blood establishments are ready to satisfy requests for immune plasma by defining the requirements applicable to plasma donors and the standards for preparation, qualification, storage, distribution, and control of product use. This Position paper aims to give recommendations on the biological characteristics of a plasma preparation from convalescent donors and to support the evaluation of this therapeutic approach in more rigorous investigations.","Blood Transfus","Accorsi, Patrizia","Berti, Pierluigi","de Angelis, Vincenzo","De Silvestro, Giustina","Mascaretti, Luca","Ostuni, Angelo","32453687"],"abstract":["Passive immunotherapy with plasma derived from convalescent patients recovering from SARS-CoV-2 infection can be a promising approach in the treatment of COVID-19 patients. It is important that blood establishments are ready to satisfy requests for immune plasma by defining the requirements applicable to plasma donors and the standards for preparation, qualification, storage, distribution, and control of product use. This Position paper aims to give recommendations on the biological characteristics of a plasma preparation from convalescent donors and to support the evaluation of this therapeutic approach in more rigorous investigations."],"journal":"Blood Transfus","authors":["Accorsi, Patrizia","Berti, Pierluigi","de Angelis, Vincenzo","De Silvestro, Giustina","Mascaretti, Luca","Ostuni, Angelo"],"date":"2020-05-27T11:00:00Z","year":2020,"_id":"32453687","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.2450/2020.0124-20","topics":["Treatment"],"weight":1,"_version_":1667983494542786562,"score":306.12497},{"pmid":32240545,"title":"Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how?","text":["Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how?","Plasma provided by COVID-19 convalescent patients may provide therapeutic relief as the number of COVID-19 cases escalates steeply worldwide. Prior findings in various viral respiratory diseases including SARS-CoV-related pneumonia suggest that convalescent plasma can reduce mortality, although formal proof of efficacy is still lacking. By reducing viral spread early on, such an approach may possibly downplay subsequent immunopathology. Identifying, collecting, qualifying and preparing plasma from convalescent patients with adequate SARS-CoV-2-neutralizing Ab titres in an acute crisis setting may be challenging, although well within the remit of most blood establishments. Careful clinical evaluation should allow to quickly establish whether such passive immunotherapy, administered at early phases of the disease in patients at high risk of deleterious evolution, may reduce the frequency of patient deterioration, and thereby COVID-19 mortality.","Vox Sang","Tiberghien, Pierre","de Lamballerie, Xavier","Morel, Pascal","Gallian, Pierre","Lacombe, Karine","Yazdanpanah, Yazdan","32240545"],"abstract":["Plasma provided by COVID-19 convalescent patients may provide therapeutic relief as the number of COVID-19 cases escalates steeply worldwide. Prior findings in various viral respiratory diseases including SARS-CoV-related pneumonia suggest that convalescent plasma can reduce mortality, although formal proof of efficacy is still lacking. By reducing viral spread early on, such an approach may possibly downplay subsequent immunopathology. Identifying, collecting, qualifying and preparing plasma from convalescent patients with adequate SARS-CoV-2-neutralizing Ab titres in an acute crisis setting may be challenging, although well within the remit of most blood establishments. Careful clinical evaluation should allow to quickly establish whether such passive immunotherapy, administered at early phases of the disease in patients at high risk of deleterious evolution, may reduce the frequency of patient deterioration, and thereby COVID-19 mortality."],"journal":"Vox Sang","authors":["Tiberghien, Pierre","de Lamballerie, Xavier","Morel, Pascal","Gallian, Pierre","Lacombe, Karine","Yazdanpanah, Yazdan"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32240545","source":"PubMed","week":"202014|Mar 30 - Apr 05","doi":"10.1111/vox.12926","keywords":["covid-19","antibody","convalescent plasma","infectious disease","plasma"],"topics":["Treatment"],"weight":1,"_version_":1666138490317832194,"score":254.85754},{"pmid":32254064,"title":"Deployment of convalescent plasma for the prevention and treatment of COVID-19.","text":["Deployment of convalescent plasma for the prevention and treatment of COVID-19.","Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease (COVID-19), has spurred a global health crisis. To date, there are no proven options for prophylaxis for those who have been exposed to SARS-CoV-2, nor therapy for those who develop COVID-19. Immune (i.e. \"convalescent\") plasma refers to plasma that is collected from individuals, following resolution of infection and development of antibodies. Passive antibody administration through transfusion of convalescent plasma may offer the only short-term strategy to confer immediate immunity to susceptible individuals. There are numerous examples, where convalescent plasma has been used successfully as post-exposure prophylaxis and/or treatment of infectious diseases, including other outbreaks of coronaviruses (e.g., SARS-1, Middle East Respiratory Syndrome [MERS]). Convalescent plasma has also been used in the COVID-19 pandemic; limited data from China suggest clinical benefit, including radiological resolution, reduction in viral loads and improved survival. Globally, blood centers have robust infrastructure to undertake collections and construct inventories of convalescent plasma to meet the growing demand. Nonetheless, there are nuanced challenges, both regulatory and logistical, spanning donor eligibility, donor recruitment, collections and transfusion itself. Data from rigorously controlled clinical trials of convalescent plasma are also few, underscoring the need to evaluate its use objectively for a range of indications (e.g., prevention vs treatment) and patient populations (e.g., age, comorbid disease). We provide an overview of convalescent plasma, from evidence of benefit, regulatory considerations, logistical work flow and proposed clinical trials, as scale up is brought underway to mobilize this critical resource. .","J Clin Invest","Bloch, Evan M","Shoham, Shmuel","Casadevall, Arturo","Sachais, Bruce S","Shaz, Beth","Winters, Jeffrey L","van Buskirk, Camille","Grossman, Brenda J","Joyner, Michael","Henderson, Jeffrey P","Pekosz, Andrew","Lau, Bryan","Wesolowski, Amy","Katz, Louis","Shan, Hua","Auwaerter, Paul G","Thomas, David","Sullivan, David J","Paneth, Nigel","Gehrie, Eric","Spitalnik, Steven","Hod, Eldad","Pollack, Lewis","Nicholson, Wayne T","Pirofski, Liise-Anne","Bailey, Jeffrey A","Tobian, Aaron Ar","32254064"],"abstract":["Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease (COVID-19), has spurred a global health crisis. To date, there are no proven options for prophylaxis for those who have been exposed to SARS-CoV-2, nor therapy for those who develop COVID-19. Immune (i.e. \"convalescent\") plasma refers to plasma that is collected from individuals, following resolution of infection and development of antibodies. Passive antibody administration through transfusion of convalescent plasma may offer the only short-term strategy to confer immediate immunity to susceptible individuals. There are numerous examples, where convalescent plasma has been used successfully as post-exposure prophylaxis and/or treatment of infectious diseases, including other outbreaks of coronaviruses (e.g., SARS-1, Middle East Respiratory Syndrome [MERS]). Convalescent plasma has also been used in the COVID-19 pandemic; limited data from China suggest clinical benefit, including radiological resolution, reduction in viral loads and improved survival. Globally, blood centers have robust infrastructure to undertake collections and construct inventories of convalescent plasma to meet the growing demand. Nonetheless, there are nuanced challenges, both regulatory and logistical, spanning donor eligibility, donor recruitment, collections and transfusion itself. Data from rigorously controlled clinical trials of convalescent plasma are also few, underscoring the need to evaluate its use objectively for a range of indications (e.g., prevention vs treatment) and patient populations (e.g., age, comorbid disease). We provide an overview of convalescent plasma, from evidence of benefit, regulatory considerations, logistical work flow and proposed clinical trials, as scale up is brought underway to mobilize this critical resource. ."],"journal":"J Clin Invest","authors":["Bloch, Evan M","Shoham, Shmuel","Casadevall, Arturo","Sachais, Bruce S","Shaz, Beth","Winters, Jeffrey L","van Buskirk, Camille","Grossman, Brenda J","Joyner, Michael","Henderson, Jeffrey P","Pekosz, Andrew","Lau, Bryan","Wesolowski, Amy","Katz, Louis","Shan, Hua","Auwaerter, Paul G","Thomas, David","Sullivan, David J","Paneth, Nigel","Gehrie, Eric","Spitalnik, Steven","Hod, Eldad","Pollack, Lewis","Nicholson, Wayne T","Pirofski, Liise-Anne","Bailey, Jeffrey A","Tobian, Aaron Ar"],"date":"2020-04-08T11:00:00Z","year":2020,"_id":"32254064","source":"PubMed","week":"202015|Apr 06 - Apr 12","doi":"10.1172/JCI138745","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Prevention","Treatment"],"weight":1,"_version_":1666138493119627264,"score":249.9143},{"pmid":32464700,"title":"Use of COVID-19 convalescent plasma in low- and middle-income countries: a call for ethical principles and the assurance of quality and safety.","text":["Use of COVID-19 convalescent plasma in low- and middle-income countries: a call for ethical principles and the assurance of quality and safety.","Most high-income countries are aggressively engaged in the collection and research evaluation of convalescent plasma as a specific passive immunotherapy for treatment of COVID-19. Preliminary clinical data fully support such initiatives. Outbreaks of COVID-19 are now dramatically affecting LMIC, which have restricted capability for ensuring organized and controlled collection of safe blood and plasma collection due to fragmented blood systems with limited oversight, infrastructure, equipment, and trained personnel. Nevertheless, there is an urgent effort in LMIC to provide COVID-19 convalescent plasma as a potentially effective therapy that can be produced locally. The Working Party on Global Blood Safety of the International Society of Blood Transfusion has published \"Points to consider in the preparation and transfusion of COVID-19 convalescent plasma in low- and middle- income countries\". The purpose of this commentary is to provide an urgent general frame of ethical and technical recommendations on the use of convalescent plasma to treat patients affected by the SARS-CoV-2 virus in LMIC. Key ethical, quality, and safety guidance for the selection of donors, the collection and processing of blood, and the transfusion of COVID-19 convalescent plasma should be followed. Governments should be reminded that an adequate supply of quality and safe blood components for transfusion is essential to meet the primary healthcare needs of the population. The response to the COVID-19 epidemic highlights the importance of capacity building for an organized and sustainable national blood system while steps are taken to provide appropriately collected, tested and processed COVID-19 convalescent plasma for investigational clinical use.","Vox Sang","Epstein, Jay","Smid, Martin","Wendel, Silvano","Somuah, Daniel","Burnouf, Thierry","32464700"],"abstract":["Most high-income countries are aggressively engaged in the collection and research evaluation of convalescent plasma as a specific passive immunotherapy for treatment of COVID-19. Preliminary clinical data fully support such initiatives. Outbreaks of COVID-19 are now dramatically affecting LMIC, which have restricted capability for ensuring organized and controlled collection of safe blood and plasma collection due to fragmented blood systems with limited oversight, infrastructure, equipment, and trained personnel. Nevertheless, there is an urgent effort in LMIC to provide COVID-19 convalescent plasma as a potentially effective therapy that can be produced locally. The Working Party on Global Blood Safety of the International Society of Blood Transfusion has published \"Points to consider in the preparation and transfusion of COVID-19 convalescent plasma in low- and middle- income countries\". The purpose of this commentary is to provide an urgent general frame of ethical and technical recommendations on the use of convalescent plasma to treat patients affected by the SARS-CoV-2 virus in LMIC. Key ethical, quality, and safety guidance for the selection of donors, the collection and processing of blood, and the transfusion of COVID-19 convalescent plasma should be followed. Governments should be reminded that an adequate supply of quality and safe blood components for transfusion is essential to meet the primary healthcare needs of the population. The response to the COVID-19 epidemic highlights the importance of capacity building for an organized and sustainable national blood system while steps are taken to provide appropriately collected, tested and processed COVID-19 convalescent plasma for investigational clinical use."],"journal":"Vox Sang","authors":["Epstein, Jay","Smid, Martin","Wendel, Silvano","Somuah, Daniel","Burnouf, Thierry"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32464700","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1111/vox.12964","keywords":["covid-19","lmic","convalescent plasma","coronavirus","transfusion"],"topics":["Prevention"],"weight":1,"_version_":1668079521337704449,"score":221.46141},{"pmid":32344202,"title":"Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development.","text":["Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development.","The pandemic spread of a novel coronavirus - SARS coronavirus-2 (SARS-CoV-2) as a cause of acute respiratory illness, named Covid-19, is placing the healthcare systems of many countries under unprecedented stress. Global economies are also spiraling towards a recession in fear of this new life-threatening disease. Vaccines that prevent SARS-CoV-2 infection and therapeutics that reduces the risk of severe Covid-19 are thus urgently needed. A rapid method to derive antiviral treatment for Covid-19 is the use of convalescent plasma derived hyperimmune globulin. However, both hyperimmune globulin and vaccine development face a common hurdle - the risk of antibody-mediated disease enhancement. The goal of this review is to examine the body of evidence supporting the hypothesis of immune enhancement that could be pertinent to Covid-19. We also discuss how this risk could be mitigated so that both hyperimmune globulin and vaccines could be rapidly translated to overcome the current global health crisis.","EBioMedicine","de Alwis, Ruklanthi","Chen, Shiwei","Gan, Esther S","Ooi, Eng Eong","32344202"],"abstract":["The pandemic spread of a novel coronavirus - SARS coronavirus-2 (SARS-CoV-2) as a cause of acute respiratory illness, named Covid-19, is placing the healthcare systems of many countries under unprecedented stress. Global economies are also spiraling towards a recession in fear of this new life-threatening disease. Vaccines that prevent SARS-CoV-2 infection and therapeutics that reduces the risk of severe Covid-19 are thus urgently needed. A rapid method to derive antiviral treatment for Covid-19 is the use of convalescent plasma derived hyperimmune globulin. However, both hyperimmune globulin and vaccine development face a common hurdle - the risk of antibody-mediated disease enhancement. The goal of this review is to examine the body of evidence supporting the hypothesis of immune enhancement that could be pertinent to Covid-19. We also discuss how this risk could be mitigated so that both hyperimmune globulin and vaccines could be rapidly translated to overcome the current global health crisis."],"journal":"EBioMedicine","authors":["de Alwis, Ruklanthi","Chen, Shiwei","Gan, Esther S","Ooi, Eng Eong"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32344202","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.ebiom.2020.102768","keywords":["covid-19","coronavirus","polyclonal hyperimmune globulin","sars-cov-2","vaccines"],"topics":["Treatment"],"weight":1,"_version_":1666138495772524545,"score":216.5673}]}